dc.contributor.advisor | Hutt, Peter Barton | en_US |
dc.contributor.author | Heinonen, Mikko | en_US |
dc.date.accessioned | 2012-06-07T20:38:50Z | |
dc.date.issued | 2002 | en_US |
dc.identifier.citation | Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws (2002 Third Year Paper) | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:8852181 | |
dc.description.abstract | The purpose of this article is to highlight the main issues raised by the Food and Drug Administration’s (“FDAâ€) approval process relating to new drugs and the treatment of this process receives in the context of the Federal Securities Laws . The partial inspiration for this article has been the recent highly publicized case concerning ImClone Systems Incorporated – a case, which well exemplifies both the connection between the valuation of a biotech/medical company and the FDA’s approval process for new drugs, and also the huge effect of the approval process to the market’s valuation of the stock price. | en |
dc.language.iso | en_US | en |
dash.license | LAA | en_US |
dc.subject | Food and Drug Law | en |
dc.subject | FDA | en |
dc.subject | securities | en |
dc.subject | disclosure | en |
dc.subject | approval | en |
dc.subject | ImClone | en |
dc.title | Disclosure of the Dealings Between Drug Developing Companies and the FDA Under the Federal Securities Laws | en |
dc.type | Paper (for course/seminar/workshop) | en_US |
dc.date.available | 2012-06-07T20:38:50Z | |
dash.authorsordered | false | |